Host response to cholestyramine can be mediated by the gut microbiota
Microbiome Research Reports · 11.07.2024 · 3 (3)
DOI: 10.20517/mrr.2023.82 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiome Research Reports, online erschienen am 11.07.2024. Verfasst von Nolan K Newman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR 97331, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
The gut microbiota has been implicated as a major factor contributing to metabolic diseases and the response to drugs used for the treatment of such diseases. In this study, we tested the effect of cholestyramine, a bile acid sequestrant that reduces blood cholesterol, on the murine gut microbiota and metabolism. We also explored the hypothesis that some effects of this drug on systemic metabolism can be attributed to alterations in the gut microbiota.
Methods
We used a Western diet (WD) for 8 weeks to induce metabolic disease in mice, then treated some mice with cholestyramine added to WD. Metabolic phenotyping, gene expression in liver and ileum, and microbiota 16S rRNA genes were analyzed. Then, transkingdom network analysis was used to find candidate microbes for the cholestyramine effect.
Results
We observed that cholestyramine decreased glucose and epididymal fat levels and detected dysregulation of genes known to be regulated by cholestyramine in the liver and ileum. Analysis of gut microbiota showed increased alpha diversity in cholestyramine-treated mice, with fourteen taxa showing restoration of relative abundance to levels resembling those in mice fed a control diet. Using transkingdom network analysis, we inferred two amplicon sequence variants (ASVs), one from the Lachnospiraceae family (ASV49) and the other from the Muribaculaceae family (ASV1), as potential regulators of cholestyramine effects. ASV49 was also negatively linked with glucose levels, further indicating its beneficial role.
Conclusion
Our results indicate that the gut microbiota has a role in the beneficial effects of cholestyramine and suggest specific microbes as targets of future investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR 97331, USA.
- Department of Biomedical Sciences, Carson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Newman, N. K., Monnier, P. M., Rodrigues, R. R., Gurung, M., Vasquez-Perez, S., Hioki, K. A., Greer, R. L., Brown, K., Morgun, A., & Shulzhenko, N. (2024). Host response to cholestyramine can be mediated by the gut microbiota. Microbiome Research Reports, 3(3). https://doi.org/10.20517/mrr.2023.82
Vancouver
Newman NK, Monnier PM, Rodrigues RR, Gurung M, Vasquez-Perez S, Hioki KA, et al. Host response to cholestyramine can be mediated by the gut microbiota. Microbiome Research Reports. 2024;3(3). doi:10.20517/mrr.2023.82
BibTeX
@article{Newman2024,
author = {Newman, Nolan K and Monnier, Philip M and Rodrigues, Richard R and Gurung, Manoj and Vasquez-Perez, Stephany and Hioki, Kaito A and Greer, Renee L and Brown, Kevin and Morgun, Andrey and Shulzhenko, Natalia},
title = {Host response to cholestyramine can be mediated by the gut microbiota},
journal = {Microbiome Research Reports},
year = {2024},
volume = {3},
number = {3},
doi = {10.20517/mrr.2023.82}
}
EUVIMED